An Open-Label, Long Term Safety Study of SD-809 ER in Subjects With Chorea Associated With Huntington Disease
Latest Information Update: 21 Oct 2022
At a glance
- Drugs Deutetrabenazine (Primary)
- Indications Chorea; Huntington's disease
- Focus Adverse reactions; Proof of concept; Registrational
- Acronyms ARC-HD; ARC-HD Switch
- Sponsors Auspex Pharmaceuticals
- 18 Oct 2022 According to a Teva Pharmaceuticals USA Media Release, this study was conducted in partnership with the Huntington Study Group (HSG).
- 18 Oct 2022 Results published in the Teva Pharmaceuticals USA Media Release.
- 15 Oct 2022 Results assessing the long-term safety and tolerability of deutetrabenazine for the treatment of Huntington disease, published in the CNS Drugs.